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Sharon Hesterlee10, Dominic J Wells11 and Kate Bushby on behalf of TACT1*Abstract
Despite multiple publications on potential therapies for neuromuscular diseases (NMD) in cell and animal models
only a handful reach clinical trials. The ability to prioritise drug development according to objective criteria is particularly
critical in rare diseases with large unmet needs and a limited numbers of patients who can be enrolled into clinical trials.
TREAT-NMD Advisory Committee for Therapeutics (TACT) was established to provide independent and objective
guidance on the preclinical and development pathway of potential therapies (whether novel or repurposed) for NMD.
We present our experience in the establishment and operation of the TACT. TACT provides a unique resource of
recognized experts from multiple disciplines. The goal of each TACT review is to help the sponsor to position the
candidate compound along a realistic and well-informed plan to clinical trials, and eventual registration. The reviews
and subsequent recommendations are focused on generating meaningful and rigorous data that can enable clear
go/no-go decisions and facilitate longer term funding or partnering opportunities. The review process thereby acts
to comment on viability, de-risking the process of proceeding on a development programme.
To date TACT has held 10 review meeting and reviewed 29 program applications in several rare neuromuscular diseases:
Of the 29 programs reviewed, 19 were from industry and 10 were from academia; 15 were for novel compounds and 14
were for repurposed drugs; 16 were small molecules and 13 were biologics; 14 were preclinical stage applications and
15 were clinical stage applications. 3 had received Orphan drug designation from European Medicines Agency and 3
from Food and Drug Administration. A number of recurrent themes emerged over the course of the reviews and we
found that applicants frequently require advice and education on issues concerned with preclinical standard operating
procedures, interactions with regulatory agencies, formulation, repurposing, clinical trial design, manufacturing and ethics.
Over the 5 years since its establishment TACT has amassed a body of experience that can be extrapolated to other
groups of rare diseases to improve the community’s chances of successfully bringing new rare disease drugs to
registration and ultimately to market.
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diseases
Neuromuscular diseases (NMD) are rare disabling con-
ditions with an unmet medical need. Within the EU
Framework Programme 6, funding was granted to a net-
work of excellence “Translational Research Europe: assess-
ment and treatment of rare inherited neuromuscular
diseases” (TREAT-NMD), tasked with ‘reshaping the transla-
tional research environment’ for these conditions. As part of
this effort, the TREAT-NMD partners developed infrastruc-
tures to support trial readiness for NMD, considering the
unique challenges of therapy development for rare diseases.
TREAT-NMD tools and resources included standardised op-
erating procedures for the assessment of animal models
[1,2], biobanks [3], patient registries [4,5], a care and trial site
registry [6], generation and dissemination of care guidelines
[7,8], evaluation and elaboration of outcome measures
[9-11], regulatory interactions [12], and an active Project Eth-
ics Council [13].
While the scope of TREAT-NMD includes all rare inher-
ited neuromuscular diseases, its initial focus was Duchenne
Muscular Dystrophy and Spinal Muscular Atrophy. In dis-
cussion with stakeholders a major gap in the field was iden-
tified. Despite hundreds of publications on potential
therapies for these diseases based on work in cell and animal
models [14], only a handful were moving forward into clin-
ical trials, and there was no systematic way for such poten-
tial therapies to be evaluated for their development
potential. In addition, where there was interest in progres-
sing along a clinical pathway, expertise to do this was lim-
ited. Academic groups and small companies frequently
lacked insight into the full implications of the drug develop-
ment process, and even large pharma often lacked know-
ledge of the specific diseases, many with no development
or regulatory precedent. Experience from other fields [15]
suggested room for improvement in enabling therapeutic
development in these rare conditions. Finally, while pa-
tient organisations and other funders were being asked to
fund therapeutic development programmes, not all of them
have established objective advisory system to appraise the
clinical potential for candidates, independent from their
existing internal scientific advisory boards who were re-
sponsible for making funding decisions.
Establishment of the TREAT-NMD advisory group for
therapeutics (TACT)
With these challenges in mind, TACT was established. A
founding chair with experience of drug development and
knowledge of the neuromuscular field worked with a
secretariat based in the TREAT-NMD co-ordination of-
fice. Together they developed the composition and terms
of reference of the group and launched TACT in 2009.
In the selection of the members of TACT, two major
considerations were applied. The first was the requirementfor multidisciplinary membership addressing the complex
and multistep nature of the drug development process and
the diverse areas of expertise it employs. The second criter-
ion was excellence. In order for the committee to have
credibility and to be used by the target community, the
members recruited had to represent the global key opin-
ion leaders in the field with genuine relevant experience.
A “core group” representative of the different disciplines
on the committee was established as a driver to oversee
the work of TACT and guide its structure and content.
All members of TACT signed a common confidential
disclosure agreement, binding for all of the information
received from applicants; conflict of interest statements
are updated on a meeting-by-meeting basis.TACT membership and procedures
Current membership of TACT includes 67 international
experts in various areas of drug development, represent-
ing 11 countries. 29 members are from Europe
(43.25%), 34 from the USA (50.75%), 3 from Australia
(4.5%), and 1 (1.5%) from South America. Representa-
tives from >10 patient groups have actively been in-
volved with TACT since 2009, helping with the selection
of projects, and providing part funding for costs. The
committee meets twice yearly, with applicants in attend-
ance. The discussion of each program takes half a day,
and is preceded by up to 10 independent reviews by
TACT committee members selected based on the most
relevant expertise. Timelines are in place for the process
of application, review and report generation (see Figure 1).
A detailed application form was devised based on the
process of drug development and designed to facilitate
comprehensive appraisal (http://www.treat-nmd.eu/
resources/tact/process/). Interested groups complete a
pre-application form and based on the required expert-
ise and a preliminary review, the TACT core group se-
lects between two and four pre-applications - which are
within the remit of TACT and at an appropriate stage of
development -to submit a full application. Completing
the application focuses the applicant on a number of im-
portant considerations critical to advancing a compound
into the clinic and beyond.
Feedback to the applicants, integrated by a lead re-
viewer from all reviews, is in a detailed written report
reflecting all aspects presented in the application and
specific questions where the applicant seeks guidance.
This report and specific recommendations are confiden-
tial, but applicants are encouraged to make the TACT
review available to interested parties such as funders on
request. A short non-confidential summary of the rec-
ommendations agreed with the applicant is posted on
the TREAT-NMD website.
Figure 1 TACT meeting timeline.
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Utilisation and outputs of TACT 2010–2014
To date TACT has held 10 review meetings, 6 in Eur-
ope and 4 in the US and reviewed 29 program appli-
cations from both academic investigators and
industry in several diseases: Duchenne Muscular Dys-
trophy, Spinal Muscular Atrophy, Becker Muscular
Dystrophy, Congenital Muscular Dystrophy, Inclu-
sion Body Myositis and X-Linked Myotubular
Myopathy.
Of the 29 programs reviewed, (Table 1) 19 (66%) were
from industry and 10 (34%) were from academia; 15
(52%) were for novel compounds and 14 (48%) were for
repurposed drugs; 15 (58%) were small molecules and 11
(42%) were biologics; 14 (48%) were preclinical stage ap-
plications and 15 (52%) were clinical stage applications.
3 had received Orphan drug designation from EMA and
3 from FDA (1 compound receiving both EMA and
FDA designation).
Applications have been received from 6 countries, 16
(55%) from USA, 12 (41%) from Europe and 1 (4%) from
Australia.Learning points
Over the course of these reviews, a number of recurrent
themes emerged frequently requiring advice and educa-
tion including:
1. Preclinical: The need to use gold standard operating
procedures for animal model experiments, for
example, utilising SOPs available via TREAT-NMD
for models of three neuromuscular diseases:
(www.treat-nmd.eu/sopdmd) (www.treat-nmd.eu/
sopsma) and (www.treat-nmd.eu/sopcmd). In a
number of cases TACTalso encouraged the applicants
to ensure their results were reproducible through
independent validation [16].
2. Regulatory: The need to seek orphan drug
designation early in the process and arrange Pre-
IND meetings (FDA) or Scientific Advice/Briefing
meeting (EMA).
3. Formulation: The lead molecule, which an applicant
is intending to take into clinical development, has to
be the one which has been evaluated pre-clinically
and for which supporting pre-clinical data are
Table 1 Previous applications (Feb 2010 – October 2014)
Name Country Disease Drug Stage of
Development
Industry/
Academia
Christopher F. Spurney, MD Children’s National
Medical Center
USA DMD Losartan/lisinopril Clinical Academia
Emilio Clementi MD, PhD & Grazia D’Angelo, MD,
PhD H Sacco University Hospital
Italy DMD Isosorbide dinitrate plus ibuprofen Clinical Academia
Giuseppe Vita, MD & Sonia Messina MD, PhD
University of Messina
Italy DMD Flavocoxid Clinical Academia
Ana Ferreiro, MD Institute of Myology France CMD N-Acetylcysteine Clinical Academia
James Symons, M.S., PhD Phrixus
Pharmaceuticals Inc
USA DMD P-188 Clinical Industry
Bradley L Hodges, PhD Prothelia Inc USA DMD Laminin-111 Preclinical Industry
Paul Higgins, PhD Paratek Pharmaceuticals USA SMA Screen of a tetracycline library one
to be selected as a final candidate
Preclinical Industry
Fredrick Sachs, PhD Rose Pharmaceuticals USA DMD GsMTx4 Preclinical Industry
Mark Blaustein Halo Therapeutics USA DMD Halofuginone (HT-100) Clinical Industry
Fabrizio Dolfi, MD, PhD NicOx SA France BMD Naproxcinod (HCT 3012) Clinical Industry
Chris N Airriess, PhD California Stem Cell USA SMA Human Embryonic Stem Cell Derived
Motor Neuron Progenitors
Clinical Industry
Fred Marin, PhD GMP-Orphan SAS France SMA Satisma (sodium phenylbutyrate) Preclinical Industry
Urs Ruegg, PhD University of Geneva Switzerland DMD Tamoxifen Preclinical Academia
Joel Braunstein, MD, FACC, MBA Tivorsan USA DMD Biglycan Preclinical Industry
Paolo Bettica, MD, PhD Italfarmaco Italy DMD Givinostat Clinical Industry
Dariusz C Gorecki MD, PhD University of Portsmouth UK DMD P2X7 Preclinical Academia
Joanne Donovan, MD, PhD Catabasis Pharma, Inc. USA DMD CAT-1004 Clinical Industry
Erica Reeves, PhD ReveraGen BioPharma, Inc. USA DMD VBP15 Preclinical Industry
Patricio Sepulveda Myostin Therapeutics Pty Ltd Australia DMD Myostin Preclinical Industry
Peter Flynn, PhD Fate Therapeutics Inc. USA DMD Wnt7a Preclinical Industry
Jon Tisley, PhD Summit PLC UK DMD SMTC 1100 Clinical Industry
Jens Schmidt, PhD University Medical Centre,
Göttingen
Germany IBM DMF/BG12 & 1400 W Preclinical Academia
Denis Guttridge, PhD Ohio State University USA DMD NBD Therapy Preclinical Academia
Carl Morris, PhD Pfizer Inc. USA DMD Anti-GDF-8 Ab Clinical Industry
Mimoun Azzouz, PhD University of Sheffield UK SMA Viral vector to deliver the
SMN transgene
Preclinical Academia
Richard Franklin, PhD Tarix Orphan LLC USA DMD TXA127 Preclinical Industry
Seth Porter, PhD FibroGen USA DMD FG-3019 Clinical Industry
Ennio Ongini, PhD & Gloria Vigliani, MD TrophyNOD France DMD Naproxcinod Clinical Industry
Suyash Prasad, MD Audentes Therapeutics USA XLMTM AAV8 Clinical Industry
For full details see http://www.treat-nmd.eu/resources/tact/reviews/past/).
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early stage, can add years to, or halt a development
programme.
4. Repurposing: Challenges of repurposing were
frequently highlighted – for example efficacy results
from other population groups may not be relevant
in the NMD population, reformulating for paediatricpopulations may not be straight forward and toxicity
studies may not be sufficient for the NMD target
population.
5. Clinical Trial design: Frequent examples of suboptimal trial
design were seen - for example plans to use small
populations to get results ‘quickly’ when power
calculations suggested the need for a larger sample
Heslop et al. Orphanet Journal of Rare Diseases  (2015) 10:49 Page 5 of 6size, selection of inappropriate outcome measures
and lack of awareness regarding specific IRB or other
regulatory restrictions when selecting a paediatric
population.
6. Manufacturing: Appropriate consideration to the
scale of the drug development process (manufacture,
upscale, partnerships for funding).
7. Ethics: Failure to consider the impact of the
proposed trial design on the target patient
population. Issues of moving forward with trials
when the proposals were not likely to yield
meaningful results. Problems of being both too
carefree and too careful about the use of relatively
invasive outcomes such as muscle biopsies.
Summary
Feedback shows that TACT recommendations have
helped investigators, including industry, in evaluating
their potential compounds in a time sensitive and cost
effective manner. Applicants are helped to consider the
development program in a methodical fashion in order
to inform clear go / no-go decisions and enable optimal
use of funding and resources. Such thought processes
are frequently new in an orphan drug environment. The
process and application form have been mirrored by
funding organisations such as patient groups in order to
assist them in determining priorities for funding, with
several applications being championed by patient organi-
sations who see the TACT process as being complemen-
tary to their internal evaluation processes. The success
of TACT cannot be measured by the number of success-
ful compounds entering clinic, but rather by the system-
atic approach to the realistic prospects for a particular
compound which, positive or negative can help the field
and applicant.
The increasingly large number of industry applicants
suggests that TACT may have a valued role in the field,
including to pharma. Key to TACT’s added value is also
that its review is not conducted with the goal of making
a funding decision or as a group funded by the prospect-
ive sponsor, but rather as an independent, centralized re-
view service on drug development potential that can
then be made accessible to many different advocacy
groups and other funding organizations. This focus on
de-risking the process of proceeding to trial and or ul-
timate registration is distinct from the role of individual
scientific funding boards.
The number of trials currently (January 2015) listed in
www.clinicaltrials.gov for DMD (N= 143) and SMA (N =
116) indicates that the field has moved on during the
5 years since the establishment of TACT, though progress
in drug approval remains disappointing. In addition to
these diseases the committee is well equipped to address
other neuromuscular diseases with large unmet need,where research is now identifying potential therapeutic
opportunities, such as Charcot-Marie-Tooth (CMT).
Other, often ‘rarer’, rare diseases are at a similar point to
where the neuromuscular field was in 2009. Mechanisms
are not clear as to how these disease communities might
be assisted to move to a point where the International
Rare Disease Research Consortium (IRDiRC) aim of 200
new therapies for rare diseases by 2020 [17] can come to
fruition. As non-profit disease funding organizations are
increasingly focused on highly translational drug develop-
ment programs, the need for access to a very sophisticated
diligence process beyond the abilities of a typical academic
advisory committee has become more apparent. Although
many organizations have been able to develop this expert-
ise through strategic hires, enhanced committees and paid
consultants, other organizations, particularly smaller ones,
do not have the resources to perform this level of dili-
gence. Also, building the same capability multiple times
over to review the same projects is not efficient. The
TACT model developed by TREAT-NMD helps meet this
growing need for sophisticated drug development dili-
gence by providing a central resource that is not “owned”
by any single funding group, but is accessible to all. We
believe that the global rare disease community, in address-
ing the ambitious aims set out by IRDiRC, should consider
the benefits of a TACT like model to add structure to help
to de-risk the process and educate the field. In rare dis-
eases, the answer to effective therapies is not so much
“more shots on goal” but “better shots on goal”—we sim-
ply can’t afford the standard high failure rate of clinical de-
velopment programs. Patients are the most valuable
resource in the process of RD drug development: we be-
lieve that the model developed by TACT is a way to im-
prove the community’s chances of successfully bringing
new RD drugs to registration and ultimately to market.
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